
Join to View Full Profile
1500 E Medical Center Dr"# 2"Ann Arbor, MI 48109
Phone+1 800-862-7284
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul McKeever, MD is a board certified pathologist in Ann Arbor, Michigan. He is currently licensed to practice medicine in Michigan, California, and South Carolina. He is a Professor at University of Michigan Medical School.
Education & Training
- Medical University of South CarolinaResidency, Pathology-Anatomic and Clinical, 1973 - 1976
- University of California (San Diego) Medical CenterInternship, Transitional Year, 1972 - 1973
- University of California, Irvine, School of MedicineClass of 1972
- University of California, Davis, School of MedicineClass of 1972
Certifications & Licensure
- MI State Medical License 1984 - 2027
- CA State Medical License 1973 - 2026
- SC State Medical License Active through 1979
- American Board of Pathology Anatomic Pathology
- American Board of Pathology Neuropathology
Publications & Presentations
PubMed
- 16 citationsCombined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.Yoshie Umemura, Daniel Orringer, Larry Junck, Maria L Varela, Molly E J West
The Lancet. Oncology. 2023-09-01 - 2 citationsWhole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib.Dongyun Zhang, William Yong, Masoud Movassaghi, Fausto J Rodriguez, Issac Yang
Biomedicines. 2022-11-08 - 1 citationsClinical Reasoning: A 59-Year-Old Man With Progressive Proximal Weakness Since Childhood.Long Davalos, Jacqueline Janecek, Yelena Fudym, Paul E. McKeever, Brian C. Callaghan
Neurology. 2021-07-14
Press Mentions
- Gene Therapy for Brain Tumor Shows Promising Early Results in HumansAugust 31st, 2023